IDH1/2-mutant Gliomas & AML (Acute Myeloid Leukemia)

IDH1 and IDH2 have a big effect on how the tumour grows and how well the patient does. These mutations happen in isocitrate dehydrogenase enzymes, which make an oncometabolite termed 2-hydroxyglutarate (2-HG). Too much 2-HG messes up normal cell metabolism, epigenetic control, and differentiation, which helps tumours grow and spread.

IDH1/2 mutations are more prevalent in lower-grade gliomas and secondary glioblastomas, frequently correlating with a more favourable overall outcome in comparison to wild-type tumours. In AML, these mutations manifest in approximately 20% of cases, predominantly in older individuals, and may coexist with additional genetic anomalies.

Finding IDH1/2 mutations has made it possible to develop tailored medicines. FDA-approved IDH inhibitors like ivosidenib (IDH1) and enasidenib (IDH2) stop the mutant enzyme from working, lower the synthesis of 2-HG, and help normal cells differentiate. These drugs have worked well in people with relapsed or refractory AML, and researchers are looking into them in clinical studies for glioma.
Molecular testing for IDH1/2 status is now a common part of the diagnostic process for both gliomas and AML. It helps doctors figure out the best course of action, plan treatment, and see if a patient is eligible for targeted medicines. This approach to precision medicine gives those who are afflicted new hope.